2025 Q2 Report: Global Trends in Biopharma Transactions Each quarter, Locust Walk’s deal team compiles key statistics and trends on […]
2025 Q1 Report: Global Trends in Biopharma Transactions Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic
China Supermarket: Is the Value for Money Due to Global Development Expertise or Superior Negotiation? Locust Walk analyzed the evolving
2024 Year-In-Review Report: Global Trends in Biopharma Transactions Each quarter, Locust Walk’s deal team compiles key statistics and trends on
2024 Q3 Report: Global Trends in Biopharma Transactions Each quarter, Locust Walk’s deal team compiles key statistics and trends on
2024 Q2 Report: Global Trends in Biopharma Transactions Each quarter, Locust Walk’s deal team compiles key statistics and trends on
Biopharma’s COVID Capital Comeback What a difference a few months can make – especially during a pandemic. Heading into 2020,
Life sciences firm Locust Walk’s plans for its $175M SPAC Geoff Meyerson co-founded Locust Walk, a Boston-based life sciences consulting
Biopharma’s COVID Capital Comeback What a difference a few months can make – especially during a pandemic. Heading into 2020,
2024 Q1 Report: Global Trends in Biopharma Transactions Each quarter, Locust Walk’s deal team compiles key statistics and trends on